BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 19071226)

  • 1. Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study.
    Cote C; Pearle JL; Sharafkhaneh A; Spangenthal S
    Pulm Pharmacol Ther; 2009 Feb; 22(1):44-9. PubMed ID: 19071226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
    Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
    Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial.
    Condemi JJ
    Clin Ther; 2001 Sep; 23(9):1529-41. PubMed ID: 11589265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance.
    Donohue JF; Hanania NA; Sciarappa KA; Goodwin E; Grogan DR; Baumgartner RA; Hanrahan JP
    Ther Adv Respir Dis; 2008 Apr; 2(2):37-48. PubMed ID: 19124357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD.
    Cazzola M; Santus P; Di Marco F; Boveri B; Castagna F; Carlucci P; Matera MG; Centanni S
    Respir Med; 2003 May; 97(5):453-7. PubMed ID: 12735659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total reversibility testing as indicator of the clinical efficacy of formoterol in COPD.
    Molimard M; Bourcereau J; Le Gros V; Bourdeix I
    Respir Med; 2005 Jun; 99(6):695-702. PubMed ID: 15878485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
    FitzGerald JM; Boulet LP; Follows RM
    Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease.
    Campbell M; Eliraz A; Johansson G; Tornling G; Nihlén U; Bengtsson T; Rabe KF
    Respir Med; 2005 Dec; 99(12):1511-20. PubMed ID: 16199148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.
    Aziz I; Hall IP; McFarlane LC; Lipworth BJ
    J Allergy Clin Immunol; 1998 Mar; 101(3):337-41. PubMed ID: 9525449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
    Broseghini C; Testi R; Polese G; Tosatto R; Rossi A
    Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study.
    Panettieri RA; MacIntyre N; Sims M; Kerwin E; Fogarty C; Noonan M; Claus R; Andrews WT
    Clin Ther; 2009 Aug; 31(8):1716-23. PubMed ID: 19808130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiles of measured and perceived bronchodilation. A placebo-controlled cross-over trial comparing formoterol and salmeterol in moderate persistent asthma.
    Schermer TR; Hoff WJ; Greefhorst AP; Creemers JP; Sips AP; Westbroek J; van Herwaarden CL
    Pulm Pharmacol Ther; 2004; 17(4):205-12. PubMed ID: 15219265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formoterol 12 microg BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or on-demand salbutamol: a multicenter, randomized, open-label, parallel-group study.
    Brambilla C; Le Gros V; Bourdeix I;
    Clin Ther; 2003 Jul; 25(7):2022-36. PubMed ID: 12946548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.
    Dalby C; Polanowski T; Larsson T; Borgström L; Edsbäcker S; Harrison TW
    Respir Res; 2009 Oct; 10(1):104. PubMed ID: 19878590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
    Bateman ED; van Dyk M; Sagriotis A
    Pulm Pharmacol Ther; 2008; 21(1):20-5. PubMed ID: 17118684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.
    Rabe KF; Timmer W; Sagkriotis A; Viel K
    Chest; 2008 Aug; 134(2):255-262. PubMed ID: 18403672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV(1) reversibility.
    Bouros D; Kottakis J; Le Gros V; Overend T; Della Cioppa G; Siafakas N
    Curr Med Res Opin; 2004 May; 20(5):581-6. PubMed ID: 15140323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doppler echocardiographic assessment of the effects of inhaled long-acting beta2-agonists on pulmonary artery pressure in COPD patients.
    Cazzola M; Mantero A; Santus P; Carlucci P; Mondoni M; Bosotti L; Centanni S
    Pulm Pharmacol Ther; 2007; 20(3):258-64. PubMed ID: 16600647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
    Appleton S; Smith B; Veale A; Bara A
    Cochrane Database Syst Rev; 2000; (2):CD001104. PubMed ID: 10796594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.